soul trial semaglutide Breaking* Top-line results positive of the highly anticipated #SOUL trial, the first powered CVOT of an oral #GLP1RA 14% reduction in MACE with oral among 9,650 people with T2D and established Oral Semaglutide Cuts Cardiovascular Risk

When regaining, the body stores more fat

They target multiple disease pathways at once

View the full release here: Following GLP-1 deprescription, weight did not significantly increase at 6 or 12 months post deprescription, compared to many well-known drug trials (in red) where patients regain up to 2/3rds of weight loss after discontinuing the drug

Frequently Asked Questions What are the benefits of taking Retatrutide

Scientific References Frequently Asked Questions Can I start GLP-1 therapy on any day of the week

Up-regulation of glutamate receptors is associated with LTP defects in the early stages of diabetes mellitus